Zika Virus has Oncolytic Activity Against Glioblastoma Stem Cells

Lubin, Jonathan A; Zhang, Ray R.; Kuo, John S.

doi:10.1093/neuros/nyy047

Cited by 32 publications

(32 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhu et al, reported that wild-type ZIKV preferentially targeted glioma stem cells (GSCs), as compared to differentiated glioma cells (DGCs) or normal neuronal cells [ 98 ]. In-line with this, another study corroborated the preferential oncolytic effect of ZIKV therapy in GSCs in vitro and the extended survival of tumor-bearing mice in a dose-dependent manner [ 99 ]. After these pivotal studies, Kaid et al demonstrated a strong and specific oncolytic property of ZIKV against human CNS embryonal tumor neurospheres and in BALB/c mice bearing orthotopic human embryonal CNS tumor xenografts [ 100 ].…”

Section: Oncolytic Viruses For Malignant Brain Tumorsmentioning

confidence: 54%

Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors

Sostoa

Dutoit

Migliorini

2020

IJMS

View full text Add to dashboard Cite

Malignant brain tumors remain incurable diseases. Although much effort has been devoted to improving patient outcome, multiple factors such as the high tumor heterogeneity, the strong tumor-induced immunosuppressive microenvironment, and the low mutational burden make the treatment of these tumors especially challenging. Thus, novel therapeutic strategies are urgent. Oncolytic viruses (OVs) are biotherapeutics that have been selected or engineered to infect and selectively kill cancer cells. Increasingly, preclinical and clinical studies demonstrate the ability of OVs to recruit T cells and induce durable immune responses against both virus and tumor, transforming a “cold” tumor microenvironment into a “hot” environment. Besides promising clinical results as a monotherapy, OVs can be powerfully combined with other cancer therapies, helping to overcome critical barriers through the creation of synergistic effects in the fight against brain cancer. Although many questions remain to be answered to fully exploit the therapeutic potential of OVs, oncolytic virotherapy will clearly be part of future treatments for patients with malignant brain tumors.

show abstract

Section: Oncolytic Viruses For Malignant Brain Tumorsmentioning

confidence: 54%

Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors

Sostoa

Dutoit

Migliorini

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Recently, because of its association with microcephaly and other severe neurological diseases, the Zika virus became an emerging flavivirus [136]. Interestingly, several studies have applied this virus to the treatment of glioblastoma-the most aggressive form of brain cancer [137][138][139]. Here, we explored the common role of MCPH gene in neurodevelopment and carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

The Yin and Yang of Autosomal Recessive Primary Microcephaly Genes: Insights from Neurogenesis and Carcinogenesis

Zhou

Zhi

et al. 2020

IJMS

View full text Add to dashboard Cite

The stem cells of neurogenesis and carcinogenesis share many properties, including proliferative rate, an extensive replicative potential, the potential to generate different cell types of a given tissue, and an ability to independently migrate to a damaged area. This is also evidenced by the common molecular principles regulating key processes associated with cell division and apoptosis. Autosomal recessive primary microcephaly (MCPH) is a neurogenic mitotic disorder that is characterized by decreased brain size and mental retardation. Until now, a total of 25 genes have been identified that are known to be associated with MCPH. The inactivation (yin) of most MCPH genes leads to neurogenesis defects, while the upregulation (yang) of some MCPH genes is associated with different kinds of carcinogenesis. Here, we try to summarize the roles of MCPH genes in these two diseases and explore the underlying mechanisms, which will help us to explore new, attractive approaches to targeting tumor cells that are resistant to the current therapies.

show abstract

“…Oncolytic virotherapy has emerged as a viable approach to revert immunosuppression in immunologically "cold" cancers, including glioblastoma (2,(5)(6)(7)(21)(22)(23)(24)(25)(26)(27)(28)(29). Here, we have used an miR-124-based oHSV attenuation system that circumvents interferon sensitivity conveyed by the commonly used infected cell protein 34.5 loss-of-function attenuation strategy (12).…”

Section: Discussionmentioning

confidence: 99%